Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia.

Nanomedicine : Nanotechnology, Biology, and Medicine
Vijaya Pooja VaikariHouda Alachkar

Abstract

CD99 is a transmembrane glycoprotein shown to be upregulated in various malignancies. We have previously reported CD99 to be highly upregulated and present a viable therapeutic target in acute myeloid leukemia (AML). Currently, no therapy against CD99 is under clinical investigation. As a surface molecule, CD99 can be targeted with an antibody-based approach. Here, we have developed a new modality to target CD99 by engineering a fusion protein composed of a single-chain variable fragment antibody (anti-CD99 scFv) conjugated with a high molecular weight elastin-like polypeptide (ELP), A192: α-CD99-A192. This fusion protein assembles into multi-valent nanoworm with optimal physicochemical properties and favorable pharmacokinetic parameters (half-life: 16 h). α-CD99-A192 nanoworms demonstrated excellent in vitro and in vivo anti-leukemic effects. α-CD99-A192 induced apoptotic cell death in AML cell lines and primary blasts and prolonged overall survival of AML xenograft mouse model.

References

Nov 1, 1995·Protein Science : a Publication of the Protein Society·C N PaceT Gray
Apr 29, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·P J ZhangJ J Brooks
Feb 13, 2001·Journal of Molecular Biology·A Wörn, A Plückthun
Jun 9, 2001·Applied Immunohistochemistry & Molecular Morphology : AIMM·Y L ChoiY L Suh
Feb 1, 2005·Journal of Immunological Methods·Eeva-Christine BrockmannPetri Saviranta
Oct 24, 2007·Particle and Fibre Toxicology·Evaldas SadauskasGorm Danscher
Jun 18, 2009·Protein Science : a Publication of the Protein Society·Trine ChristensenAshutosh Chilkoti
May 7, 2010·Plant Biotechnology Journal·Udo ConradJürgen Scheller
Dec 8, 2011·The Journal of Biological Chemistry·Meike HuttRoland E Kontermann
Feb 4, 2014·ACS Nano·Suhaas Rayudu AluriJohn Andrew MacKay
Nov 19, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jordan DespanieJ Andrew MacKay
Nov 12, 2016·Oncotarget·Maria Cristina ManaraKatia Scotlandi
Jan 27, 2017·Science Translational Medicine·Stephen S ChungChristopher Y Park
Aug 10, 2017·Biophysical Journal·Mads NygaardKresten Lindorff-Larsen
Oct 26, 2018·Journal of Controlled Release : Official Journal of the Controlled Release Society·Hao GuoJ Andrew MacKay
Aug 3, 2019·Haematologica·Vijaya Pooja VaikariHouda Alachkar

❮ Previous
Next ❯

Citations

Aug 30, 2020·International Journal of Molecular Sciences·Changrim LeeJ Andrew MacKay

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.